FERRAU', Francesco
 Distribuzione geografica
Continente #
NA - Nord America 6.545
EU - Europa 5.976
AS - Asia 3.192
SA - Sud America 990
Continente sconosciuto - Info sul continente non disponibili 337
AF - Africa 97
OC - Oceania 3
AN - Antartide 1
Totale 17.141
Nazione #
US - Stati Uniti d'America 6.308
RU - Federazione Russa 3.352
SG - Singapore 1.293
CN - Cina 943
BR - Brasile 835
IE - Irlanda 582
IT - Italia 523
SE - Svezia 495
HK - Hong Kong 326
DE - Germania 219
VN - Vietnam 207
GB - Regno Unito 180
PL - Polonia 177
FR - Francia 174
IN - India 88
CA - Canada 82
FI - Finlandia 80
BD - Bangladesh 74
AR - Argentina 48
MX - Messico 48
UA - Ucraina 40
TR - Turchia 36
ZA - Sudafrica 30
ID - Indonesia 29
BE - Belgio 27
CO - Colombia 25
JP - Giappone 24
EC - Ecuador 22
IQ - Iraq 22
NL - Olanda 21
UZ - Uzbekistan 21
AT - Austria 20
CR - Costa Rica 20
PK - Pakistan 19
MA - Marocco 18
VE - Venezuela 18
ES - Italia 15
CZ - Repubblica Ceca 14
PE - Perù 14
GT - Guatemala 13
HN - Honduras 12
NI - Nicaragua 12
LT - Lituania 11
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
IL - Israele 10
KE - Kenya 10
PH - Filippine 10
PR - Porto Rico 10
MY - Malesia 9
SV - El Salvador 9
EG - Egitto 8
JM - Giamaica 8
JO - Giordania 8
KG - Kirghizistan 8
TT - Trinidad e Tobago 8
AL - Albania 7
CW - ???statistics.table.value.countryCode.CW??? 7
TN - Tunisia 7
NP - Nepal 6
PY - Paraguay 6
UY - Uruguay 6
CH - Svizzera 5
CI - Costa d'Avorio 5
EE - Estonia 5
OM - Oman 5
PA - Panama 5
AZ - Azerbaigian 4
BO - Bolivia 4
DZ - Algeria 4
SN - Senegal 4
SY - Repubblica araba siriana 4
BY - Bielorussia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
HR - Croazia 3
KH - Cambogia 3
KZ - Kazakistan 3
LV - Lettonia 3
MD - Moldavia 3
NG - Nigeria 3
PT - Portogallo 3
SC - Seychelles 3
AM - Armenia 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
CG - Congo 2
DK - Danimarca 2
ET - Etiopia 2
GP - Guadalupe 2
GR - Grecia 2
LB - Libano 2
LC - Santa Lucia 2
LK - Sri Lanka 2
NO - Norvegia 2
RS - Serbia 2
SR - Suriname 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
Totale 16.795
Città #
Ashburn 961
Moscow 923
Singapore 685
Dublin 582
Chandler 482
Dallas 478
San Jose 458
Beijing 343
Hong Kong 323
Nyköping 300
Council Bluffs 183
The Dalles 171
Warsaw 164
Messina 161
Los Angeles 146
Jacksonville 125
Munich 110
Princeton 103
New York 102
Medford 93
Lauterbourg 92
Ann Arbor 74
Dearborn 73
Des Moines 73
Cambridge 64
Santa Clara 62
São Paulo 61
Ho Chi Minh City 57
Lancaster 55
Brooklyn 42
Buffalo 42
Atlanta 40
Hanoi 40
Shenyang 40
Redondo Beach 38
Orem 36
Jinan 34
Tianjin 34
Boardman 33
Houston 33
Frankfurt am Main 31
Milan 30
North Bergen 30
Guangzhou 29
Seattle 28
Wilmington 28
London 27
Rio de Janeiro 27
Brussels 26
Catania 26
Hyderabad 26
Helsinki 24
Phoenix 24
Turku 24
Belo Horizonte 23
Denver 23
Montreal 23
Nanjing 22
Rome 21
Chicago 20
Curitiba 20
Tashkent 20
Tokyo 19
Johannesburg 17
San Francisco 17
San Mateo 17
Toronto 17
Jakarta 15
Mexico City 15
San José 15
Vienna 15
Brasília 14
Chennai 14
Dong Ket 14
Naples 14
Pune 14
Stockholm 14
Zhengzhou 14
Nanchang 13
Ankara 12
Bremen 12
Düsseldorf 12
Hangzhou 12
Poplar 12
Shenzhen 12
Bogotá 11
Campinas 11
Columbus 11
Managua 11
Manchester 11
Nuremberg 11
Porto Alegre 11
Haikou 10
Hillsboro 10
Ningbo 10
Shanghai 10
Taizhou 10
Woodbridge 10
Baghdad 9
Boston 9
Totale 8.953
Nome #
Cyberknife stereotactic treatment of pituitary adenomas: A single center experience using different irradiation schemes and modalities 325
Effects of cyberknife radiotherapy treatment of pituitary adenomas 300
Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study 300
Aggressive pituitary adenomas: the dark side of the moon 293
Aggiornamento sulla chirurgia ipofisaria per via endoscopica: indicazioni, vantaggi e limiti 261
Acromegaly is more severe in patients with AHR or AIP gene variants living in highly polluted areas 257
Biochemical control and clinical improvement is induced by long-term pasireotide administration in the majority of patients with Cushing[apos]s disease persistent after pituitary surgery 256
Oral mucositis induced by treatment with soft gel formulation of levothyroxine 236
Global Cushing's disease epidemiology: a systematic review and meta-analysis of observational studies 227
Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide 220
Diabetes secondary to acromegaly: Physiopathology, clinical features and effects of treatment 219
Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. 218
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 209
Global epidemiology of acromegaly: A systematic review and meta-analysis 199
Course of Pregnancy in Cushing Disease under Different Management Approaches (No Treatment, Surgery, Gamma-Knife or Ketoconazole) 193
Peptide receptor radionuclide therapy with 111IN-DTPA-Octreotide in a woman with Cabergoline-resistant giant prolactinoma 190
Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study 190
An extremely rare association of TSH-secreting pituitary adenoma, metastatic neuroendocrine tumor and Cushing’s syndrome in a patient with MEN-1 gene mutation 190
Comment to ‘glucocorticoid resistance syndrome caused by a novel nr3c1 point mutation’ by al argan et al. 190
Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden 188
P-57 Increased prevalence of acromegaly in an industrialized area of north-east of Sicily: a case-control study 187
High bone marrow fat in patients with Cushing’s syndrome and vertebral fractures 185
Effectiveness and safety of long-term pegvisomant administration in patients with acromegaly not controlled by other therapies: experience of an Italian center. 182
Increased prevalence of acromegaly in a highly polluted area. 182
Increased serum interleukin-22 levels in patients with PRL-secreting and non-functioning pituitary macroadenomas. 181
Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas 179
PRIMARY EMPTY SELLA IS ASSOCIATED WITH INCREASED CARDIOVASCULAR RISK, REGARDLESS THE OCCURRENCE OF PITUITARY DYSFUNCTION 178
GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly 175
Adrenal Cushing Syndrome: Diagnosis and Management in a 10-Year-Old Boy with Carney Complex 173
Increased prevalence of restless legs syndrome in patients with acromegaly and effects on quality of life assessed by Acro-QoL. 173
Course of pregnancies in women with Cushing's disease treated by gamma-knife 171
Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly 171
Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide 171
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 164
Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective 164
Epidemiologia degli adenomi ipofisari nel nord-est della Sicilia 163
MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior 161
First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy 160
Multidisciplinary management of pituitary apoplexy 158
Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing's disease. 157
Resistance to somatostatin analogues is associated with GSTP1 gene methylation and AHR rs2066853 variant in acromegaly patients 157
Environmental Endocrinology and Endocrine Disruptors: Environmental Impact on the Hypothalamus–Pituitary Axis 156
A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score 154
Thyroid nodules in growth hormone replaced patients. 153
Osilodrostat (LCI699) per la cura della sindrome di Cushing 152
Effects of pasireotide treatment on cardio-metabolic risk in patients with Cushing's disease: an Italian, multicenter study 152
Increased interleukin 22 circulating levels in patients with tumors involving the hypothalamic-pituitary region 151
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 150
Establishment of a protocol to extend the lifespan of human hormone-secreting pituitary adenoma cells 150
Genetic and epigenetic modulation of AHR pathway in GH-secreting pituitary tumors and effects on acromegaly clinical phenotype 148
Absence of GNAS1 mutations in somatotropinomas from AIPmut positive patients: possible implications for phenotype. 146
Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence 144
An unusual case of idiopathic hyperprolactinemia 143
Effects Of Epigenetic Changes In Gstp1 And Mgmt Gene On Clinicopathological Fatures Of Acromegaly Patients 143
Temozolomide-induced shrinkage of a pituitary carcinoma. 142
Epidemiology, course, and outcomes of Sars-CoV-2 infection in patients with acromegaly and Cushing’s disease: a monocentric experience in Southern Italy 141
Increased serum brain natriuretic peptide levels are a major predictor of myocardial hypertrophy in acromegalic patients. 140
First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. 139
Health-related quality of life in patients with Cushing's syndrome 138
Germline targeted next-generation sequencing in patients with adrenal incidentalomas 134
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 133
Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma 131
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis 129
The man with acromegaly who inspired the Shrek animated project. 129
Endocrinologia & Malattie del Metabolismo 129
Persistent severe visual field impairment is associated with obesity and tumour invasiveness, but not with pituitary dysfunction, in patients with craniopharyngioma 128
Pitfalls in the 2017 TNM Classification of Thyroid Carcinoma 125
Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma 122
A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas 119
Paradoxical GH increase during OGTT is associated to first-generation somatostatin analogs responsiveness in acromegaly 119
Trabecular bone score, bone marrow fat and vertebral fractures in cushing syndrome 118
Are comorbidities of patients with adrenal incidentaloma tied to sex? 118
Somatic Deletion in Exon 10 of Aryl Hydrocarbon Receptor Gene in Human GH-Secreting Pituitary Tumors 116
New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study 115
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches 114
Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies 113
Pregnancy after azathioprine therapy for ulcerative colitis in a woman with autoimmune premature ovarian failure and Addison's disease: HLA haplotype characterization. 111
Metabolic comorbidities in Cushing's syndrome 111
X-linked acrogigantism: a new condition of growth hormone excess. 110
Italian Guidelines for the Management of Prolactinomas 106
What we have to know about corticosteroids use during Sars-Cov-2 infection 106
Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report 106
How to diagnose and manage Cushing's disease during pregnancy, when hypercortisolism is mild? 105
Epidemiological analysis to identify predictors of X-linked hypophosphatemia (XLH) diagnosis in an Italian pediatric population: the EPIX project 104
Immunohistochemical localization and functional characterization of somatostatin receptor subtypes in a corticotropin releasing hormone-secreting adrenal phaeochromocytoma: review of the literature and report of a case 103
The gene of the ubiquitin-specific protease 8 is frequently mutated in adenomas causing cushing's disease 100
Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms 100
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients 99
The ubiquitin-specific peptidase 8 (USP8) gene is frequently mutated in adenomas causing Cushing's disease 97
GPR101 variants in acromegaly: results from a large series of patients. 96
Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas 96
Endocrine disruptors, aryl hydrocarbon receptor and cortisol secretion 94
Landscape of familial isolated and young-onset pituitary adenomas: Prospective diagnosis in AIP mutation carriers 91
Unique clinical picture in patients with X-linked acrogigantism 90
Metabolic syndrome in cushing's syndrome patients 90
Systemic comorbidities induce early vascular alterations in patients with active acromegaly. 89
What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study 89
Approccio al paziente con tumore ipofisario aggressivo 88
Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications 88
Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor 87
Totale 15.343
Categoria #
all - tutte 56.627
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.627


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022544 0 0 0 0 18 10 27 23 10 95 119 242
2022/20231.710 162 177 77 132 112 157 36 91 683 14 43 26
2023/2024453 31 76 22 42 39 102 6 46 2 28 4 55
2024/20252.616 54 36 70 168 171 78 86 484 606 204 268 391
2025/20267.951 438 462 582 500 746 1.617 933 970 989 384 155 175
2026/20272.262 187 1.028 418 520 109 0 0 0 0 0 0 0
Totale 17.141